Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V

Progresses Acromegaly programme towards clinic

13-May-2011 - United Kingdom

Syntaxin announced a manufacturing agreement with SynCo Bio Partners B.V. Under the agreement, SynCo will manufacture SXN101959, Syntaxin’s lead internal candidate for acromegaly, discovered from its Targeted Secretion Inhibitor (TSI) platform.

Acromegaly is a chronic and debilitating disease resulting from the excessive secretion of growth hormone. Syntaxin’s molecule, SXN101959, is in development for the therapeutic treatment of Acromegaly as a primary indication.

Dr Melanie Lee, CEO of Syntaxin, commented: “SynCo’s manufacturing capability provides us with the means to rapidly move SXN101959 through to Phase I clinical trials in Acromegaly. Progress of SXN101959 towards the clinic follows a recent announcement that our partnered molecule AGN-214868, has entered Phase II in post-herpetic neuralgia (PHN) as a primary indication.” Dr Lee added, “These molecules demonstrate the enormous potential of the platform to generate new treatments for a range of diseases. Aberrant secretion underpins many aspects of cancer, inflammatory, endocrine and gastro-intestinal diseases”.

Pierre Warffemius, CEO of SynCo Bio Partners, commented: “SynCo is pleased to be working with Syntaxin on the manufacture of SXN101959 for the treatment of Acromegaly. We aim to establish a long-term relationship with Syntaxin to support its unique TSI platform and expanding product portfolio, by providing high quality manufacturing and filling services”.

In Acromegaly, hypersecretion of growth hormone usually occurs from a benign pituitary tumour. Current first line therapy is the use of somatostatins to reduce secretion, however, up to 60% of patients are refractory to this treatment so there is a significant unmet need for new products. Syntaxin’s TSI mechanism of action provides a unique and potentially superior approach to the inhibition of growth hormone release.

Under the agreement, SynCo will manufacture multiple batches of SXN101959 drug substance for the non-clinical and clinical programme. The manufacturing programme at SynCo Bio has commenced, with technical transfer of the manufacturing process and analytical release and stability assays from Syntaxin.

https://www.bionity.com/en/news/132431/syntaxin-enters-manufacturing-agreement-with-synco-bio-partners-b-v.html